血液透析联合血液灌流在终末期肾病患者治疗中的应用

目的 探究血液透析联合血液灌流在终末期肾病患者治疗中的应用效果。方法 选取我院2016年1月~2018年12月治疗的终末期肾病患者94例，其中47例接受血液透析治疗，为对照组；另外47例接受血液透析联合血液灌流治疗，为试验组。比较两组治疗前后的血清β2微球蛋白（β2-MG）、甲状旁腺激素（PTH）、血肌酐（Scr）、尿素氮（BUN）和临床疗效。结果 试验组β2-MG、PTH、Scr和BUN水平分别为（2.94±0.52）mg/L、（251.64±20.42）pg/L、（532.69±114.31）μmol/L和（10.58±2.68）mmol/L，均低于对照组的［（4.89±0.64）mg/L、（270.83±22.45）pg/L、（580.25±118.57）μmol/L和（13.44±3.59）mmol/L］，差异有统计学意义（P＜0.05）。试验组治疗总有效率高于对照组（93.62% vs 78.72%），差异有统计学意义（P＜0.05）。结论 对终末期肾病患者采用血液透析联合血液灌流治疗，有利于改善患者的各项生理指标，提高临床疗效。

Application of Hemodialysis Combined with Blood Perfusion in the Treatment of Patients withEnd-stage Renal Disease

Abstract:Objective To explore the effect of hemodialysis combined with blood perfusion in the treatment of patients with end-stage renal disease. Methods A total of 94 patients with end-stage renal disease treated in our hospital from January 2016 to December 2018 were enrolled. Among them, 47 patients underwent hemodialysis treatment as the control group. Another 47 patients underwent hemodialysis combined with hemoperfusion as the test group. Serum β2 microglobulin (β2-MG), parathyroid hormone (PTH), serum creatinine (Scr), urea nitrogen (BUN) and clinical efficacy were compared before and after treatment. Results The levels of β2-MG, PTH, Scr and BUN in the test group were (2.94±0.52) mg/L, (251.64±20.42) pg/L, (532.69±114.31) μmol/L and (10.58±2.68) mmol/L, respectively,were lower than the control group (4.89±0.64) mg/L, (270.83±22.45) pg/L, (580.25±118.57) μmol/L and (13.44±3.59) mmol/L], the difference was statistically significant (P<0.05). The total effective rate of the test group was higher than that of the control group (93.62% vs 78.72%),the difference was statistically significant (P<0.05). Conclusion Hemodialysis combined with hemoperfusion in patients with end-stage renal disease is beneficial to improve various physiological indicators and improve clinical efficacy.